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Abstract Attention-deficit/hyperactivity disorder (ADHD)
is one of the most common psychiatric disorders in chil-
dren and adolescents, with up to 5 % affected worldwide.
Twin and family studies on ADHD show its high famili-
ality with heritability estimated around 70 %, but, to date,
no specific polymorphism or gene was found to be spe-
cifically affected. Psychostimulants (amphetamine, meth-
ylphenidate) and non-psychostimulants (atomoxetine) are
used successfully in ADHD therapy, but many of their
mechanisms of action and their adverse effects are not yet
fully understood. Therefore, both genetic findings and
therapeutic interventions should be further investigated.
One easy platform for such studies is in vitro analyses,
which encompass neuronal cell culture studies, transfec-
tions of genetic constructs, binding and electrophysiology
analyses. In this review, different methods will be referred
in particular to ADHD findings, and new techniques will be
mentioned for future studies of drug or genetic effects in
vitro.
Keywords Atomoxetine  Attention-deficit hyperactivity
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of
the most common psychiatric disorders in children and
adolescents, with up to 5 % affected worldwide and with
similar prevalence rates throughout different cultural set-
tings (Polanczyk et al. 2007). ADHD is characterised as a
clinically heterogeneous neurodevelopmental syndrome by
the constitutive development of inappropriate levels of
inattention, hyperactivity, and impulsiveness. The syndro-
mal dimensions of inattention and enhanced-impulsivity
are increasingly recognised as highly persistent into
adulthood and are associated with considerable risk for
psychiatric co-morbidity, such as depression, substance
abuse disorder, and failure in psychosocial adaptation
(Jacob et al. 2007).
State-of-the-art treatments for ADHD include parental
training, psychotherapeutic-behavioural therapy, and social
interventions. According to the European Network for
Hyperkinetic Disorders (EUNETHYDIS) Guideline Group,
in severe cases and impairment, the use of medication is
recommended (Banaschewski et al. 2008). Medications
currently licenced for the treatment of children and ado-
lescents with ADHD include psychostimulants, such as
methylphenidate hydrochloride (MPH) and dexamfetamine
sulphate, and as second choice the non-stimulant ato-
moxetine (ATX). MPH, which reduces the core symptoms
of the disorder and improves patients’ quality of life, is the
first-line treatment for ADHD. Stimulant medications are
usually titrated until reaching optimal symptom reduction
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or until significant stimulant side effects occur. In the
European guidelines of medication for ADHD (Graham
et al. 2011), it is summarised that side effects occur, but
they are generally acceptable because they are mild and/or
temporary. MPH has a neuropharmacological profile sim-
ilar to amphetamine and cocaine, which are well known as
indirect dopamine (DA) agonists that cause a striatal DA
overflow, probably via DA transporter (DAT) inhibition
and partial norepinephrine transporter (NET) inhibition
(Challman and Lipsky 2000). ATX, a non-psychostimu-
lant, is known to act via norepinephrine (NE) reuptake
inhibition (Dell’Agnello et al. 2009). However, a need for
further clarification of the mechanisms of action of the
various drug therapies still exists.
The cause and pathophysiology of ADHD is still
unknown, but there is clear evidence that ADHD has
multiple aetiologies (e.g. an interaction of genetic, envi-
ronmental, neurobiological, and neurochemical factors)
(Purper-Ouakil et al. 2011). ADHD shows high heritability
as documented in family, twin, and adoption studies, with
estimates of up to a 70 % heredity rate (Faraone and Doyle
2001). To date, although several genome-wide association
studies (GWAS) and meta-analyses for association studies
were conducted, no one single nucleotide polymorphism
(SNP) or gene was found to be specifically affected in
ADHD (Zhang et al. 2012). Still, it seems that dopami-
nergic, serotonergic, noradrenergic, synaptic, and growth
factors genes are involved in ADHD. Therefore, some
functional mechanism of action of such genetic findings
might reveal the etiopathology of ADHD.
In vitro studies are one possible route in the quest to find
the etiopathology of ADHD as well as the mechanism of
action of its drug therapy. In vitro analyses span can be
applied to cell culture studies of vesicular and synaptic
release, binding, and electrophysiology analysis. In this
review, different methods will be applied to ADHD find-
ings, and new techniques will be mentioned for future
studies of drug or genetic effects in vitro.
Cell culture studies
Several studies have been conducted on cell cultures, either
non-neuronal transfected cultures or neuronal cells (pri-
mary/cell lines) and astrocytic cells in order to elucidate
the effects of drug therapy or the function of the trans-
porter/receptor thought to be involved in ADHD. Most of
these studies involve toxicity/cell viability tests as well as
morphological analysis of the cells.
Non-neuronal culture
The toxicity effect of MPH was tested on non-neuronal
human embryonic kidney (HEK-293) cells and HEK-293
cells stably transfected with the human DAT gene (HEK-
hDAT) as a model limited to the inhibiting effects of MPH
on DAT (Ludolph et al. 2006). Ludolph et al. (2006)
demonstrated that no toxicity effect could be observed in
both HEK-293 and HEK-hDAT cells treated with MPH at
doses of 1–1,000lM, as measured with an MTT assay. In
addition, they showed that MPH (250–1,000 lM) reduced
cytotoxicity caused by 1-methyl-4-phenylpyridinium
(MPP?) in HEK-hDAT cells. In a later study by Schmidt
et al. (2010a), the effect of psychostimulants and ATX on
cell survival of immune (monocytic U-937) cells was tes-
ted. Similar to Ludolph et al.’s study, Schmidt et al.
(2010a) also found increased cell survival, while ATP
measurements for energy metabolism of the cells revealed
no effect what-so-ever. Furthermore, Schmidt et al.
(2010b) tested whether psychostimulants and ATX affect
the transcription of 8-hydroxyguanine glycosylase 1
(hOGG1), which catalyses the removal of 8-hydroxy-20-
deoxyguanosine (8-oxo-OHdG), one of the predominant
products of oxidative DNA lesions induced by reactive
oxygen species. After U-937 cell treatment with various
doses of amphetamine, MPH or ATX, they extracted total
RNA for reverse-transcription polymerase chain reaction
(RT-PCR) for the hOGG1 gene. They observed decreased
expression of hOGG1 mRNA at a significant level after
treatment with 5,000 ng/ml amphetamine as well as after
treatment with 50, 500, and 5,000 ng/ml ATX (Schmidt
et al. 2010b). Therefore, they concluded that these drugs
play a protective role against oxidative DNA damage.
In order to learn the functional differences of DA or NE
transport blockage, one could use transfected cells bearing
the DAT or NET. The possibility of whether transporters
can promote cellular adaptation, analogous to receptors,
was raised. In HEK cell lines transfected with the hDAT,
human DAT, its substrates (DA, amphetamine), and clini-
cally relevant DAT inhibitors (cocaine, MPH and bupro-
pion) reportedly increased c-Fos immunoreactivity (Yatin
et al. 2002). To demonstrate this novel catecholamine
transporter-dependent function, Yatin et al. developed an
immunofluorescent method to quantify c-Fos in individual
cells. Increased expression of the immediate early gene
c-fos initiates a cascade of intracellular events that may
underlie neuroadaptive changes following repeated expo-
sure to the drugs. Yatin et al. (2005) investigated whether
substrates (DA, NE) of the human DAT and NET can
directly induce c-Fos protein in HEK cells transfected with
hDAT and hNET and whether protein kinase C (PKC)
modulators affect this process. This group’s demonstration
that DA and NE can induce c-Fos expression in a mono-
amine transporter-dependent manner suggests the possi-
bility that elevated catecholamine levels induced by
psychostimulant drugs of abuse, such as cocaine and
amphetamine, as well as clinically relevant medications
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such as MPH and bupropion, may affect gene expression
and serve as a trigger for neuroadaptive responses in neu-
rons expressing monoamine transporters (Yatin et al.
2005).
Transfected cell cultures are another useful tool in
exploring the functional effects of known mutations asso-
ciated with ADHD. For example, the 40-bp variable
number of tandem repeats (VNTR) polymorphism in the
15th exon of DAT1 (SLC6A3) (Vandenbergh et al. 1992a,
b) is known to reside in a region encoding the 30 untrans-
lated region (30-UTR), which does not alter the protein’s
amino acid sequence, but the 10-repeat variant is report-
edly associated with ADHD (Nemoda et al. 2011). In a
study in which HEK cells were transfected with four dif-
ferent DAT1 constructs (hDAT, DAT1 coding the region
necessary and sufficient to produce a functional transporter
protein; hDAT Zero, a construct containing the DAT1
coding region flanked by an *800-bp fragment of the 30-
UTR upstream of the VNTR region; hDAT 9, a construct
with the DAT1 coding region upstream of a full length 30-
UTR harbouring the 9-repeat VNTR; hDAT 10, a construct
with the DAT1 coding region upstream of a full length 30-
UTR containing the 10-repeat VNTR), VanNess et al.
(2005) examined the effects of the DAT1 VNTR on mea-
sures of in vitro DAT expression and pharmacology. They
were able to demonstrate that DAT expression, as mea-
sured using binding assays and DAT immunoblotting, is
attributed to the DAT1 genotype. Cells carrying the
10-repeats DAT1 variants were characterised by a Bmax
approximately 50 % greater than cells with the 9-repeat
VNTR; those containing only the DAT1 coding region or
the coding region flanked by a truncated 30-UTR resulted in
greater DAT density than either of the naturalistic 9- and
10-repeat variants (VanNess et al. 2005). On the other
hand, competition-binding assays showed no statistically
significant DAT1 genotype effects on the DAT affinity for
MPH, as expected (VanNess et al. 2005).
In studying the transport of drugs into the central ner-
vous system (CNS), Zhu et al. (2008a) used the porcine
kidney epithelial cell line LLC-PK1 and its human P-gly-
coprotein overexpressing mutant LLC-PK1/MDR1 cells.
They investigated whether the P-glycoprotein, a member of
the adenosine triphosphate-binding cassette transporter
superfamily that has been found in a large number of
normal tissues including intestine, liver, placenta, kidney,
and the blood–brain barrier (BBB), interacts in the drug
transport of ATX, MPH, amphetamine, and modafinil (Zhu
et al. 2008a). Since it is known that in the BBB, P-glyco-
protein prohibits substrate drug penetration into the CNS
(Mayer et al. 1997; van Asperen et al. 1997), Zhu et al.
(2008a) used intracellular uptake studies with fluorescent
substrates doxorubicin and rhodamine123 as well as a cell
monolayer culture of the transport efficiencies. Their
results demonstrated that all tested agents with the excep-
tion of modafinil isomers are relatively weak P-glycopro-
tein inhibitors. Furthermore, P-glycoprotein may play a
minor role in the transport of D-MPH, D-modafinil, and
L-modafinil. The same research group established another
cell line that stably expressed specific mutation of the
human carboxylesterase (CES)1 (Zhu et al. 2008b). CES1
is the principal enzyme governing the metabolism of MPH
and is involved in the metabolism of numerous other
therapeutic medications as well as some illicit drugs, such
as heroin and cocaine. The mutation in exon 4 of CES1 is
located in codon 143 and leads to a non-conservative
substitution (Gly143Glu), which results in a reduction of
enzyme activity and complete loss of hydrolytic activity
towards methylphenidate. This specific CES1 mutation was
also investigated in a Hungarian ADHD group (Nemoda
et al. 2009), but no genotype effect could be shown.
However, the group of Nemoda could detect that carrying
the Glu-allele required lower doses of MPH for symptom
reduction and so it seems that the mutation has an impact
on MPH response and should be further investigated in
larger ADHD samples.
Neuronal culture
Similar to the non-neuronal cell culture, the toxic effect of
MPH was also tested on primary cultures from rat rostral
mesencephalic tegmentum (Ludolph et al. 2006). An MTT
assay demonstrated no toxicity effects of MPH on the
neurons, and an additional immunocytochemistry and
morphological analysis proved no effects on the dopami-
nergic neurons [measured as tyrosine-hydroxylase (TH)
positive neurons] (Ludolph et al. 2006). MPH has also
proved protective effects against MPP? in this cell culture,
a result similar to the non-neuronal culture (Ludolph et al.
2006). Again, Schmidt et al. (2010a) tested various psy-
chostimulants and ATX for their toxicity effect on human
neuroblastoma SH-SY5Y cells. As with the non-neuronal
cell culture, MPH and ATX also enhanced cell survival
(Schmidt et al. 2010a). As described above, in the non-
neuronal cell culture, Schmidt et al. (2010b) also demon-
strated a decreased hOGG1 mRNA expression after treat-
ment with psychostimulants or ATX of the SH-SY5Y cells.
Recently, our study group tested the effects of MPH on
dopaminergic neuronal cell culture devoid of DAT (Bartl
et al. 2011). Through this system, we could test MPH
effects on the cells that are not associated with DAT
inhibition. For this study, we used rat pheochromocytoma
cells (PC12) that do not express DAT, but do express NET.
MPH’s influence in a dose response was tested for neuro-
transmitter levels (release, metabolism, and cytoplasmic)
using high-performance liquid chromatography (HPLC).
Gene expression levels of synaptic genes were tested using
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the quantitative RT-PCR (Q-PCR), and cell proliferation
studies using bromodeoxyuridine (BrdU) were conducted.
Treatment with low-dose MPH (1–100 nM) altered intra-/
extracellular neurotransmitter levels, down-regulated all
investigated genes (NET (SLC6A2), synaptotagmin 1 and
4, syntaxin 1a, and synaptic vesicle glycoprotein 2C), and
significantly enhanced cell proliferation. These data point
to the diverse effects of MPH on cell metabolism inde-
pendent of inhibiting DAT (Bartl et al. 2011). This study
did not investigate the effects of MPH on other uptake
systems, for example, organic cation transporters (OCT) or
plasma membrane monoamine transporter (PMAT). Daws
(2009) reported in detail that in addition to traditional
uptake systems like DAT, NET, or serotonin transporter
(SERT), OCT and/or PMAT are capable of clearing bio-
genic amines from extracellular fluid and may serve to
buffer the effects of frontline antidepressants, MPH and
amphetamine. The role of OCT in the mechanism of action
of MPH is not known so far, but it seems to be a very
important aspect and, in addition to DAT inhibition, should
be taken into account for future MPH studies.
The internalisation and recycling of the DAT on the
membrane surface was studied since PKC was demon-
strated to down-regulate DA transport, primarily by redis-
tributing the DAT from the plasma membrane to
endosomal compartments, which might play an important
role in treatment with psychostimulants (Loder and Meli-
kian 2003). For this purpose, Loder and Melikian used
PC12 cells that stably expressed the human DAT (DAT-
PC12). For the effects of DAT internalisation and recy-
cling, they used cell surface biotinylation and then SDS–
polyacrylamide gel electrophoresis and immunoblotting. In
this study, they demonstrate constitutive DAT trafficking,
and that PKC-mediated DAT sequestration is achieved by a
combination of accelerated internalisation and reduced
recycling (Loder and Melikian 2003).
Astrocytes and glial culture
Since it was reported that astrocytes, which are the most
numerous glial cells in the CNS, play an important role in
the development of synaptic plasticity induced by meth-
amphetamine (Miyatake et al. 2005; Narita et al. 2005,
2006), Suzuki et al. (2007) investigated whether treatment
with MPH could affect the morphology of astrocytes,
compared to methamphetamine. Here, they used limbic
neuron/glia co-cultures from newborn mice that were
treated in a dose response study with MPH or metham-
phetamine for 3 days. The effects on activated astrocytes
were visualised using fluorescence immunocytochemistry
with a mouse polyclonal antibody against glial fibrillary
acidic protein (GFAP). From this study, it can be con-
cluded that treatment with methamphetamine, but not
MPH, caused long-lasting astrocytic activation in limbic
neuron/glia co-cultures. These findings suggest that, unlike
methamphetamine, MPH induces reversible astrocytic
activation after washout (Suzuki et al. 2007). Narita et al.
(2009) investigated the involvement of phosphatidylinis-
itol-3 kinase (PI3-K) in astrocyte activation. Administra-
tion of a selective PI3-K inhibitor wortmannin, together
with methamphetamine or MPH, markedly and signifi-
cantly inhibited methamphetamine-/MPH-induced astro-
cyte activation, suggesting the involvement of PI3-K in
this process. In primary neuron/glia co-cultures, a high
concentration of methamphetamine dose-dependently
reduced the number of cells positive for microtubule-
associated protein 2a/b (MAP2a/b), which is a marker for
neuronal dendrites; in contrast, MPH treatment did not
change the number of MAP2a/b-positive cells. Narita
et al. (2009) then measured the immunoreactivity of
cleaved caspase-3, which is an activated form of apop-
tosis-related protein caspase-3, in order to reveal whether
the reduction of MAP2a/b positive cells is due to apop-
tosis. They found that a high concentration of metham-
phetamine induced cleaved caspase-3, whereas the same
treatment with MPH did not induce cleaved caspase-3.
The above-mentioned homology between the reduction of
MAP2a/b-positive cells and the induction of cleaved
caspase-3 implies that a high concentration of metham-
phetamine in primary neuron/glia co-cultures causes
neuronal cell death. In contrast, MPH lacks such an effect.
Recently, since NE activation of b-adrenergic receptors
has been observed to induce the synthesis of the chemokine
monocyte chemoattractant protein (CCL2/MCP-1) in
astrocytes, the mechanisms involved in this process, par-
ticularly the possible effect of NE modulating drugs, was
tested (Hinojosa-Arango et al. 2009). In this study, the
authors used primary rat astrocyte cultures treated with
NET inhibitors, either desipramine or ATX. The expression
and synthesis of CCL2/MCP-1 in these cells were inves-
tigated using Q-PCR, enzyme-linked immunosorbent assay
(ELISA), and immunocytochemsitry methodologies. Both
drugs induced an increase in CCL2/MCP-1 expression in
astrocytes (Hinojosa-Arango et al. 2009). These results
suggest that CCL2/MCP-1 expression could also be mod-
ulated by some mechanism independent of the elevation of
brain NE levels. This was confirmed by measuring a
reduction in CCL2/MCP-1 production by treatment with
clonidine, a a2 adrenergic receptor agonist.
Drug binding and transport inhibition
Since many of the ADHD drug therapies involve inhibition
of synaptic DA or NE uptake, binding and uptake inhibi-
tion potency assays are an important part of drug-effect
studies. One possibility for such an investigation is either
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using cell cultures that harbour the transporter of interest or
using stably transfected cells. These are then used for an
uptake assay with a radioactive-marked substance or for a
ligand-binding assay using a radioligand and a nonradio-
active competitor. Such study was conducted by Ukairo
et al. (2007) who investigated the influences on DAT
function at the level of the cultured cell by addressing the
following: the age of the cell line (measured by cell pas-
sage number), the density of the cell monolayer (i.e., per-
cent confluence), and the effect of varying DAT expression
levels by manipulation of transfection conditions. To
ensure that comparisons between DA uptake inhibition
potency (DUIP) and apparent binding affinity were legiti-
mate for a given DAT inhibitor, [3H]-DA uptake assays,
binding assays involving the cocaine analogue [3H]-WIN
35,428, and versions of each assay that included competitor
nonradioactive DAT blockers were conducted under iden-
tical conditions. To address, in part, the physiological rel-
evance of such a phenomenon, neuronal and non-neuronal
cell lines were similarly tested for DAT inhibitor DUIP
fluctuations. Fluctuations in DUIP were observed for
classical DAT blockers including cocaine, mazindol, MPH,
and benztropine in CHO cells expressing wild type DAT
(Ukairo et al. 2007). Cocaine potency also decreased in
DAT-expressing non-neuronal COS-7 cells and murine
neuroblastoma (N2A) cells (Ukairo et al. 2007). In con-
trast, the DAT substrate amphetamine did not display this
DUIP fluctuation. In parallel experiments, no fluctuation
was observed for the apparent binding affinities of these
five drugs. The DUIP decrease appeared to correlate with
an increase in cell surface DAT expression level, as mea-
sured by Bmax values and confocal microscopy. The fact
that the DUIP profile of amphetamine diverged from that of
the classical DAT blockers is consistent with the idea
of fundamental differences between the mechanisms of
abused psychostimulant DAT substrates and inhibitors
(Ukairo et al. 2007).
Such binding and affinity study was also able to dem-
onstrate the differences between the two isomers of MPH,
the D- and L-threo-isomers (Markowitz et al. 2006;
Markowitz and Patrick 2008). Markowitz et al. (2006,
2009) demonstrated that MPH has affinity for the seroto-
nergic 5-HT1A and 5-HT2B receptor sites for both D- and
L-MPH, with D-MPH exerting by far the most predominant
effects. In addition, they showed a marked difference in
affinity to NET between the D- and L-isomers, of which
D-MPH exhibited prominent affinity.
Electrophysiology
Electrophysiological studies, on either brain slices or single
cells using patch clamp with electro- or chemical-excita-
tion, are useful tools to investigate the inhibition/activation
of drugs, such as MPH and ATX. For example, MPH was
shown to increase cortical excitability via activation of
a2-noradrenergic receptors (Andrews and Lavin 2006).
Similarly, in another study, it was demonstrated that
the MPH-induced response is probably mediated by NE
via a2B/2C-adrenoceptors in locus coeruleus neurons
(Ishimatsu et al. 2002). In a later study, whole-cell patch-
clamp recordings revealed that MPH enhances inhibitory
synaptic transmission by increasing the concentration of
NE at noradrenergic synapses in juvenile rat locus coe-
ruleus neurons (Kidani et al. 2010). On the other hand,
in the dopaminergic neurons originating from the ventral
tegmental areas, Prieto-Gomez et al. (2004, 2005)
hypothesised after electrophysiological study on brain
slices that psychostimulants sensitisation could be
involved, though both N-Methyl-D-aspartate (NMDA) and
kainite/AMPA glutamate receptors medicated the excit-
ability of these neurons.
ATX has also been studied for its mechanism of action
using electrophysiological methods. Kobayashi et al.
(2010) investigated the effects of ATX and reboxetine on
G-protein-activated inwardly rectifying K? (GIRK) chan-
nels using the Xenopus oocyte expression assay. In oocytes
injected with mRNA for GIRK1/GIRK2, GIRK2, or
GIRK1/GIRK4 subunits, an extracellular application of
ATX or reboxetine reversibly reduced GIRK currents. The
inhibitory effects were concentration dependent, but volt-
age-independent, and time-independent during each volt-
age pulse (Kobayashi et al. 2010). Such findings were
suggested to point to the therapeutic effects of NET
inhibitors and their adverse side effects related to the ner-
vous system and heart function. In addition, a recent pub-
lication by Ludolph et al. (2010) demonstrated effective
NMDA receptor antagonism by ATX at low micromolar
concentrations in different cell culture models. Therefore,
it was proposed that the antagonism at the NMDA recep-
tors by ATX might contribute to the clinical effect in
ADHD.
Studies of specific genetic mutations using electro-
physiological techniques could also be useful in under-
standing the effects of such mutations on neurotransmitter
efflux, as demonstrated by Bowton et al. (2010). They
report that tonic activation of the D2 receptor provides
support for hDAT A559V-mediated anomalous DA efflux.
These studies identify a signalling network downstream of
D2 receptor activation, normally constraining dopaminer-
gic action at synapses that may be altered by DAT mutation
to impact risk for ADHD.
Future prospective and methods
Recently, several new in vitro methods have emerged to be
potentially useful in studies associated with ADHD genetic
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mechanisms of action or drug function. Such methods
could provide additional knowledge for better under-
standing of the disorder and/or potential targets for new
therapy developments.
Stem cells
Since ADHD is considered a neurodevelopmental disorder,
understanding how genes function in human brain devel-
opment and how they interact with each other to cause a
psychiatric disorder would be of great value. Mouse and
human stem cells can teach us a great deal about how
typical differentiation programs are implemented and how
they may be modified in disease. But since stem cells are
usually derived from embryos, the work with human stem
cells has been hampered by ethical concerns. One alter-
native to embryonic stem cells is tissue-specific stem cells
from adult humans. Stem cells of the central nervous sys-
tem, from the subventricular zone of the cerebral cortex
and the subgranular zone of the dentate gyrus, are of
obvious interest for neuropsychiatric disorders. But again,
this is quite limited because to harvest such cells, one needs
fresh tissue, usually obtained from biopsies. Recently, the
enormous advantages of induced pluripotent stem cells
(iPSCs), commonly derived from skin fibroblasts, have been
discussed (see Review, Vaccarino et al. 2011). The fact that
such cells are derived from a living person using a non-
controversial cell type, are generated from a specific indi-
vidual, maintain his/her genetic constitution and diversity,
and can represent a source of differentiated cell types
genetically compatible with the person of origin has great
advantage. Specifically, examination of iPSCs from typically
developing individuals will reveal how basic cellular pro-
cesses and genetic differences contribute to individually
unique nervous systems. Moreover, by comparing iPSCs
from typically developing individuals and patients, differ-
ences at stem cell stages, through neural differentiation, and
into the development of functional neurons may be identified
that will reveal opportunities for intervention. The applica-
tion of such techniques to early onset neuropsychiatric dis-
orders is still on the horizon but has become a reality of
current research efforts because of the revelations of many
years of basic developmental neurobiological science.
Impedance-based method of cell proliferation/
differentiation monitoring (xCELLigence)
To date, the cell culture studies for cell viability, cell death,
proliferation, or differentiation rely on endpoint analysis.
Thus, one of the major limitations in the interpretation of
such analyses in time course is derived from the fact that
extensive and laborious endpoint measurements in separate
cultures are required to cover a sufficient amount of time
points for interpretation of the kinetic. Therefore, such
limitations of standard endpoint assays in vitro may be
overcome using an impedance-based analysis system for
the detection of cell viability (xCELLigence, Roche).
Consequently, cell populations that differ in cell density,
proliferation rate, adhesion characteristics, or cell mor-
phology can be distinguished by the impedance readout
(Xiao et al. 2002). Recently, this system was also tested for
detection of neuronal cell death and compared to mea-
surements of endpoint viability (Diemert et al. 2012). They
could validate the xCELLigence system for real-time
detection of cell death in a neuronal cell line of immorta-
lised hippocampal neurons (HT-22 cells), neuronal pro-
genitor cells (NPC), and differentiated primary cortical
neurons (Diemert et al. 2012). They found a good corre-
lation between impedance measurements and endpoint
viability assays in HT-22 cells and NPC for detecting
proliferation, cell death kinetics, and also the neuropro-
tective effects of pharmacological apoptosis inhibitors.
However, in primary neurons, they could not detect den-
dritic outgrowth during differentiation of the cells. Cell
death in primary neurons was detectable by the xCELLi-
gence system; however, the changes in the cell index based
on impedance measurements depend to a great extent on
the severity of the insult. Therefore, this new method
presents great potential in studying cell cultures in a con-
tinuous real-time-course that can reveal the effects previ-
ously missed using conventional methods.
Live-cell imaging
The advantages of live-cell imaging have been discussed in
many previous reviews (Meijering et al. 2009; Tsien 2003).
The ability to visualise cells and subcellular dynamic
processes in space and time has been made possible by
revolutionary developments in imaging technology in the
past two decades. Advances in molecular biology, organic
chemistry, and materials science have resulted in an
impressive toolbox of fluorescent proteins (GFP and vari-
ants) and nanocrystals (quantum dots) and have enabled the
study of protein expression, localisation, conformation,
diffusion, turnover, trafficking, and interaction (Giepmans
et al. 2006; Lippincott-Schwartz and Patterson 2003).
Hardware advances in optical systems design have taken
light microscopy from wide field to (multiphoton) confocal
and spinning disk microscopy (Stephens and Allan 2003),
and more recent efforts to break the diffraction barrier have
further extended the palette (Garini et al. 2005; Hell 2009).
Together, these developments have redefined biological
research by enabling the switch from fixed to living cells
and from qualitative to quantitative imaging (Tsien 2003).
The understanding of synaptic plasticity kinetics will
advance neuroscience greatly in regard to understand how
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neurons store information, how spatiotemporal patterns of
synaptic input combined with postsynaptic neuronal
activity produce neuronal plasticity, and how plasticity
changes neuronal activity patterns (Kotaleski and Black-
well 2010). Live-cell imaging techniques together with
new computer modelling may provide much higher reso-
lution views into synaptic plasticity (Kotaleski and
Blackwell 2010). Similarly, protein trafficking dynamics
are now available using fluorescently tagged proteins,
enabling visualisation of protein movements and correla-
tion of a protein’s dynamics with its changing structural
state or ligand binding (Chamberlain and Hahn 2000). A
newly developed technique is reported to observe DNA-
methylation states in live-cell imaging using fluorescent
probes that bind specifically to methylated DNA (Yamag-
ata 2010). Such new aspects will allow the observation of
epigenetic changes due to environmental alterations with
time, which have not yet been available. Other techniques
to visualise synaptic vesicle recycling (Kakazu et al. 2012)
or the exocytosis of membrane proteins (Hildick et al.
2012) were reported to be successful in live-cell imaging.
To date, few studies using live-cell imaging associated
with ADHD have been conducted. Still, Bolan et al. (2007)
investigated the role of two D2 receptor-linked signalling
pathways [extracellular signal-regulated kinase (ERK1/2)
and the PI3-K] in mediating the D2 receptor regulation of
DAT using the fluorescent DAT substrate 4-(4-(dimethyl-
amino)-styryl)-N-methylpyridinium (ASP?) in live-cell
imaging techniques. This study could show that an increase
in DAT function is ERK1/2-dependent but PI3-K-inde-
pendent, which therefore suggests the possibility of a direct
physical interaction between DAT and the D2 receptor
(Bolan et al. 2007). ASP? was also demonstrated to be
feasible in analysing the function of the serotonin trans-
porter in HEK and neuroblastoma cells (Oz et al. 2010).
Conclusion
Since the aetiology of ADHD is not yet fully revealed, and
only some genetic and environmental factors that affect the
neurodevelopmental processes have been suggested, the
importance of further research in this field is rather obvi-
ous. Psychostimulants (e.g., amphetamine, MPH) and non-
psychostimulants (e.g., ATX) are used successfully in
ADHD therapy, but many of their mechanism of action and
their adverse effects are not yet fully understood. There-
fore, both genetic findings and therapeutic effects should be
further investigated. In conclusion, using in vitro systems
to investigate the function of genes involved in ADHD or
the mechanism of action of drug therapy is a very valuable
tool in ADHD research. In addition, the new techniques
mentioned in this article as well as new to come can
enhance our understanding of many processes that have not
yet been revealed.
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